NEUBASE THERAPEUTICS INC (NBSE) Stock Price, Quote, News and Overview
NASDAQ:NBSE - Nasdaq - US64132K2015 - Common Stock - Currency: USD
NBSE Quote, Performance and Key Statistics
0.378
-0.01 (-3.2%)
The current stock price of NBSE is 0.378 USD. In the past month the price decreased by -13.84%. In the past year, price decreased by -90.27%.
NBSE Competitors/Peers
Symbol | Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 17.17 | 307.29B | ||
| AMGN | AMGEN INC | 14.05 | 149.69B | ||
| GILD | GILEAD SCIENCES INC | 22.89 | 131.53B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 1691.57 | 126.11B | ||
| REGN | REGENERON PHARMACEUTICALS | 12.83 | 64.02B | ||
| ARGX | ARGENX SE - ADR | 322.75 | 36.66B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | N/A | 30.76B | ||
| ONC | BEIGENE LTD-ADR | N/A | 27.27B | ||
| BNTX | BIONTECH SE-ADR | N/A | 25.20B | ||
| SMMT | SUMMIT THERAPEUTICS INC | N/A | 20.17B | ||
| NTRA | NATERA INC | N/A | 19.56B | ||
| BIIB | BIOGEN INC | 7.22 | 17.40B |
Related stock screener links
About NBSE
Company Profile
NeuBase Therapeutics, Inc. is a biotechnology company, which engages in the development of drugs for patients with genetic neurological disorders. The company is headquartered in Pittsburgh, Pennsylvania. The company went IPO on 2014-05-28. The company is developing a modular peptide-nucleic acid (PNA) antisense oligo (PATrOL) platform to address genetic diseases, with a single, cohesive approach. The Company’s programs are NT-0100 in HD, NT-0200 in myotonic dystrophy type 1 (DM1) and NT-0300 in KRAS-driven cancers. The NT-0100 program is a PATrOL-enabled therapeutic program being developed to target the mutant expansion in the HD DNA or RNA. The NT-0200 program is a PATrOL-enabled therapeutic program being developed to target the mutant expansion in the DM1 disease RNA. The NT-0300 program is a PATrOL-enabled therapeutic program being developed to target the mutated KRAS gene. The company uses its platform to address diseases which have a genetic source, with an initial focus on gene silencing in DM1, Huntington’s disease (HD), and oncology and in gene editing applications. The company also focused on identifying and evaluating multiple indications for potential development.
Company Info
NEUBASE THERAPEUTICS INC
350 Technology Drive
Pittsburgh PENNSYLVANIA 15219 US
CEO: Dietrich Stephan
Employees: 37
Company Website: https://www.neubasetherapeutics.com/
Phone: 14127633350
NEUBASE THERAPEUTICS INC / NBSE FAQ
What is the stock price of NEUBASE THERAPEUTICS INC today?
The current stock price of NBSE is 0.378 USD. The price decreased by -3.2% in the last trading session.
What is the ticker symbol for NEUBASE THERAPEUTICS INC stock?
The exchange symbol of NEUBASE THERAPEUTICS INC is NBSE and it is listed on the Nasdaq exchange.
On which exchange is NBSE stock listed?
NBSE stock is listed on the Nasdaq exchange.
What is the price forecast or stock price prediction for NEUBASE THERAPEUTICS INC stock?
6 analysts have analysed NBSE and the average price target is 142.8 USD. This implies a price increase of 37677.78% is expected in the next year compared to the current price of 0.378. Check the NEUBASE THERAPEUTICS INC stock analysts ratings, price target forecast and up-and down grades for more detailed information.
What is NEUBASE THERAPEUTICS INC worth?
NEUBASE THERAPEUTICS INC (NBSE) has a market capitalization of 1.42M USD. This makes NBSE a Nano Cap stock.
How many employees does NEUBASE THERAPEUTICS INC have?
NEUBASE THERAPEUTICS INC (NBSE) currently has 37 employees.
What are the support and resistance levels for NEUBASE THERAPEUTICS INC (NBSE) stock?
NEUBASE THERAPEUTICS INC (NBSE) has a resistance level at 0.42. Check the full technical report for a detailed analysis of NBSE support and resistance levels.
Should I buy NEUBASE THERAPEUTICS INC (NBSE) stock?
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
- The Technical Analysis (TA) tab contains a technical analysis of NBSE, looking at technical quality and support and resistance levels
- The Fundamental Analysis (FA) tab contains a fundamental analysis of NBSE, evaluating the profitability, health, valuation and growth aspects
- NEUBASE THERAPEUTICS INC (NBSE) Price Target Forecast and Analysts Ratings to understand what professional analysts say.
- NEUBASE THERAPEUTICS INC (NBSE) Sales and EPS estimates to see what analysts future expectations are.
- NEUBASE THERAPEUTICS INC (NBSE) Income, Balance Sheet and Cash Flow statements to dive into the historical financials.
- NEUBASE THERAPEUTICS INC (NBSE) Insider and Institutional Ownership to learn about the owners and their transactions.
- NEUBASE THERAPEUTICS INC (NBSE) Stock Chart to make your own analysis
- NEUBASE THERAPEUTICS INC (NBSE) Latest news and press-releases to stay up to date.
Does NEUBASE THERAPEUTICS INC (NBSE) stock pay dividends?
NBSE does not pay a dividend.
When does NEUBASE THERAPEUTICS INC (NBSE) report earnings?
NEUBASE THERAPEUTICS INC (NBSE) will report earnings on 2024-08-12.
What is the Price/Earnings (PE) ratio of NEUBASE THERAPEUTICS INC (NBSE)?
NEUBASE THERAPEUTICS INC (NBSE) does not have a PE ratio as the earnings reported over the last twelve months were negative (-7.3).
NBSE Technical Analysis
NBSE Fundamental Analysis
ChartMill assigns a fundamental rating of 2 / 10 to NBSE. While NBSE seems to be doing ok healthwise, there are quite some concerns on its profitability.
NBSE Financial Highlights
Over the last trailing twelve months NBSE reported a non-GAAP Earnings per Share(EPS) of -7.3. The EPS increased by 55.05% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -73.74% | ||
| ROE | -150.22% | ||
| Debt/Equity | 0 |
NBSE Ownership and Analysts
ChartMill assigns a Buy % Consensus number of 43% to NBSE. The Buy consensus is the average rating of analysts ratings from 6 analysts.